NCT03067935
No Longer Available
不适用
Individual Patient Expanded Access-Glembatumumab Vedotin
概览
- 阶段
- 不适用
- 状态
- No Longer Available
概览
简要总结
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is 18 years of age or older.
- •The patient has histologically confirmed, gpNMB expressing, metastatic triple-negative breast cancer
- •Overexpression of gpNMB in at least one tumor sample as determined by a Sponsor approved laboratory using IHC methods
- •The patient does not have abnormal organ function, active autoimmune disease, active infections or additional concurrent conditions that would compromise the patient's ability to safely receive glembatumumb vedotin.
- •The patient is not eligible for or cannot access ongoing glembatumumab vedotin clinical trials
- •The patient does not qualify for, or cannot access, other comparable or satisfactory alternative therapy for triple negative breast cancer.
- •The patient is able to read and understand, and has signed a patient informed consent form, which outlines the nature of the proposed treatment and the anticipated benefits and risks of treatment with glembatumumab vedotin.
排除标准
- •History of allergic reactions attributed to compounds of similar composition to glembatumumab vedotin, MMAE, dolastatin or auristatin.
- •Pregnant or breast-feeding women, and women or men who are not willing to use effective contraception during the time from signing of informed consent through two months after the last dose of glembatumumab vedotin treatment.
- •The patient was previously treated with glembatumumab vedotin or previously enrolled on the METRIC trial (regardless of which arm they were randomized to).
- •Any underlying medical condition that, in the investigator's or Sponsor's opinion, will make the administration of Glembatumumab vedotin hazardous to the patient, or would obscure the interpretation of adverse events.
研究者
相似试验
No Longer Available
不适用
Expanded Access (Compassionate Use) Treatment Protocol RindopepimutRecurrent GBMNCT03068650Celldex Therapeutics
Unknown
不适用
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCISpinal Cord Injury at C5-C7 LevelNCT03925649Hope Biosciences LLC
No Longer Available
不适用
Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaMultiple MyelomaNCT03126617Bristol-Myers Squibb
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelMantle Cell LymphomaAcute Lymphoblastic LeukemiaNCT05776134Kite, A Gilead Company
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company